Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 125

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 125
---
, brokers and other financial institutions. Dividend Policy We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any cash dividends will be within the discretion of our Board at such time. 70 CAPITALIZATION The following table sets forth our cash and our capitalization as of September 30, 2024, on:

| ● | an            
 actual basis; |

| ● | on                                                                                            
 an as adjusted basis giving effect to (i) the exercise of 2,462 Preferred Warrants for 2,462  
 shares of Series A Preferred Stock and the receipt of the cash proceeds of such exercises,    
 (ii) the conversion of 3,484 shares of Series A Preferred Stock into 759,369 shares of Common 
 Stock, including the shares of Series A Preferred Stock set forth in clause (i), (iii) the    
 conversion of 213 shares of Series B Preferred Stock into 41,376 shares of Common Stock,      
 (iv) the issuance of 247,914 warrants to purchase shares of Common Stock and (v) the issuance 
 of 436,384 shares of Common Stock pursuant to the Keystone Equity Financing, in each case     
 from October 1, 2024 through January 8, 2025; and                                             |

| ● | on                                                                                                                                     
 a pro forma basis, giving effect to the adjustments in the preceding bullet and the issuance and sale of 4,000,000 shares of Common    
 Stock in this offering at the assumed public offering price of $2.34 per share, which is the last reported sale price of our Common    
 Stock on the Nasdaq Global Market on January 8, 2025, and after deducting placement agent fees and estimated offering expenses payable 
 by us and assuming no sale of Pre-Funded Warrants in this offering and no exercise of Offered Common Warrants.                         |

All information in this section gives retroactive effect to the Reverse Stock Split. You should read this information in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus, the information set forth in “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information contained elsewhere in this prospectus.

|                                                                                      |     |         | September 30, 
          2024 |   |     |          | September 30, 
          2024 |   |     |